Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Insulin, Regular, Human · Afrezza

Recombinant protein · Agonist of insulin receptor (INSR) · developed by Mannkind

Approved FDA, Jun 2014
MNKD Developer
2 Registered trials

What is Insulin, Regular, Human?

Insulin Regular Human (Afrezza) is a rapid-acting inhaled human insulin that lowers blood glucose by binding the insulin receptor, stimulating peripheral glucose uptake by skeletal muscle and fat and inhibiting hepatic glucose production. It is used to improve glycemic control in patients with diabetes mellitus, and is studied in type 1 and type 2 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Afrezza
Drug type
Recombinant protein
Targets
insulin receptor (INSR)
Mechanism
Agonist of insulin receptor (INSR)
Pathways
glucose uptake by skeletal muscle and fat, hepatic glucose production inhibition, lipolysis inhibition, protein synthesis
Therapy area
Endocrine, Metabolic
Developer
Mannkind (MNKD)
FDA status
Approved as Afrezza (June 27, 2014), BLA022472 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of May 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05243628 Phase 4 Type 1 Diabetes Completed MNKD
NCT04125082 Phase 4 Type 2 Diabetes Treated With Insulin Unknown MNKD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type 1 DiabetesType 2 Diabetes Treated With Insulin

Other drugs acting on INSR

More from Mannkind

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MNKD page.

Follow MNKD, the company behind Insulin, Regular, Human

See MNKD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MNKD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.